Clinical Value Of Interferon-γ Releasing Assay In Differentiating Intestinal Tuberculosis And Crohn’s Disease

Objective: To evaluate the value of two interferon-γ releasing assays(IGRA) in differential diagnosis of intestinal tuberculosis(ITB) and Crohn’s disease(CD).Methods: Databases of Embase, PubMed, EBM Reviews, CNKI, Wanfang were searched for evaluating the value of IGRA in differential diagnosis of ITB and CD between establishment and January 2016.The Meta-Disc was used to calculate the pooled sensitivity, specificity and 95% confidence interval(95%CI). Summary receiver operating characteristic curve(SROC), area under curve(AUC) and Q* were used to evaluate the efficiency of the two methods.Results:Totally 12 articles were included, including 854 patients(ITB 367, CD 487). The pooled sensitivity and specificity for T-SPOT.TB were 0.89(95%CI=0.84 to 0.93)and 0.85(95%CI=0.81 to 0.89). The pooled sensitivity and specificity for Quantiferon-TB were 0.72(95%CI=0.64 to 0.79)and 0.92(95%CI=0.86 to 0.96). The AUC of SROC for the two methods were 0.9450 and 0.9110, and the Q* were 0.8839 and 0.8432. There was no statistically difference between the two methods(P=0.164).Conclusion:T-SPOT.TB and Quantiferon-TB have high sensitivity and specificity and are both effective ways for the differential diagnosis of ITB and CD. But there was no statistically difference between the two methods.